NCDB Announces New Breast Quality Measure

The Commission on Cancer (CoC) National Cancer Database (NCDB) has announced a new breast quality measure, which took effect June 27:

BCSdx—Breast measure: First therapeutic breast surgery in a non-neoadjuvant setting is performed within 60 days of diagnosis for patients with American Joint Committee on Cancer Clinical Stage I-III breast cancer

This quality measure will be included in the Rapid Cancer Reporting System (RCRS) and will not be reviewed for compliance for Standard 7.1.

In anticipation of additional quality measure changes in 2023, the following changes to existing RCRS quality measures will be made. Effective January 2023, these four measures will be removed from RCRS and will not be evaluated to determine compliance with Standard 7.1:

Radiation following any mastectomy with >4 positive regional lymph nodes
Tamoxifen or third generation aromatase inhibitor T1cN0M0 or stage IB-III hormone receptor positive breast cancer
Image or palpation-guided needle biopsy to the primary site before resection
Surgery is not the first course of treatment for stage III lung cancer